Medtronic plc (NYSE: MDT) is scheduled to report first quarter 2020 earnings results on Tuesday, August 20, before the opening bell. Analysts expect the company to report earnings of $1.18 per share on revenue of $7.4 billion.
This compares to revenues of $7.3 billion and adjusted earnings of $1.17 per share reported in the first quarter of 2019.
The company has been seeing revenue declines in its Cardiac and Vascular Group for the past few quarters. Revenues in the Diabetes Group also saw a drop last quarter. The performance of these segments will be an area to watch. The Minimally Invasive Therapies Group and the Restorative Therapies Group have posted revenue growth consistently over the past couple of quarters and this trend can be expected to continue in the first quarter.
During the first quarter, Medtronic completed the acquisition of Titan Spine and updates on this topic will be noteworthy. The acquisition will help further Medtronic’s strategy to transform spinal procedures and improve outcomes. The deal is expected to be immaterial to fiscal year 2020 adjusted EPS.
The company has also entered into various partnerships in order to improve and diversify its product offerings and updates on this area will be worth noting.
In the fourth quarter of 2019, Medtronic topped market expectations for revenue and earnings. Worldwide revenue was flat at $8.1 billion on a reported basis but rose 3.6% on an organic basis. Adjusted EPS grew 8% to $1.54. Revenues grew in the single digits range in the US and emerging markets but declined in non-US developed markets.
For fiscal year 2020, Medtronic has guided for organic revenue growth of 4% and adjusted EPS in the range of $5.44-5.50.
Shares of Medtronic have gained 13% thus far this year and 2% in the past one month. The majority of analysts have rated the stock as Buy and the average 12-month price target is $107.08.